Towards Healthcare
AAV Gene Therapy Market Booms at 40.1% CAGR by 2034

AAV Gene Therapy Market 2025 Key Players Include Novartis, Roche and Spark Fuel Global Race for Rare Disease Cures

According to market projections, the AAV gene therapy sector is expected to grow from USD 2.75 billion in 2024 to USD 78.56 billion by 2034, reflecting a CAGR of 40.1%. This AAV gene therapy market growth is driven by emerging trends and strong demand across key sectors. The rising demand for gene therapy and growing genomics research boost the market. North America led the global market due to the presence of state-of-the-art research and development facilities and favorable regulatory policies.

Content

  • Insight Code: 5810
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The AAV gene therapy market stands at USD 3.85 billion in 2025 and is expected to reach USD 78.56 billion by 2034, growing at a CAGR of 40.1% from 2024 to 2034.\r\n

North America is leading the AAV gene therapy market due to the availability of state-of-the-art research and development facilities, technological advancements, and favorable regulatory policies.

The AAV gene therapy market includes seven segments including by therapeutic area, by vector serotype, by route of administration, by application stage, by manufacturing type, by end-user, and by region.

Some key players include Novartis, Regenxbio, and Genethon.

Key trends include the growing demand for gene therapy, the rising prevalence of genetic disorders, and increasing investments.

A carrier called a vector is first genetically engineered to deliver the gene. Adenovirus vector gene therapy works by introducing the DNA into the nucleus of the cell.

AAV virus is used as a vector for gene delivery in various studies, including the development of vaccines and gene-based antibody delivery of protective immunity.

Clinicaltrials.gov, Canadian Organization for Rare Disorders, German Center for Infection Research, Food and Drug Administration
Any Questions